WAYNE, PA — Cagent Vascular, Inc. has announced a strategic partnership with 3comma Medical GmbH to accelerate the international adoption of the Serranator® PTA Serration Balloon Product Family. Through this agreement, 3comma Medical will act as the exclusive distributor in the European Union (EU) and Middle East and North Africa (MENA) regions, leveraging its industry expertise and extensive network to bring innovative vascular solutions to new markets.
The Serranator is a cutting-edge device used in the treatment of peripheral artery disease (PAD) and chronic limb threatening ischemia (CLTI). The product’s novel serration technology aims to enhance precision and effectiveness in treating these conditions. The collaboration marks a significant milestone for Cagent, which has seen notable success in the U.S. market and is now poised for broader international growth.
“We are excited to join forces with 3comma to accelerate adoption in international markets,” said Paul Wilson, Chief Commercial Officer of Cagent Vascular. “Partnering with 3comma marks an exciting step forward in expanding global access to the Serranator portfolio and delivering cutting-edge solutions to patients around the world.”
3comma Medical’s CEO and Managing Partner, Marc Paris, added, “We are thrilled to partner with Cagent Vascular and bring Serranator to physicians worldwide. Cagent’s commitment to delivering high-quality products for PAD and CLTI will be a valuable addition to the institutions we serve.”
By combining Cagent’s innovative technology with 3comma’s distribution capabilities, the partnership aims to enhance treatment options for patients and improve outcomes on a global scale. Looking ahead, both companies plan to build on this momentum, further reinforcing their commitment to advancing solutions for PAD and CLTI patients worldwide.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.